#AAN25: J&J, argenx keep rolling out myasthenia gravis data, plus more
Last weekend, researchers gathered in San Diego for the American Academy of Neurology’s annual meeting to discuss the latest advancements and clinical trial data across the neuroscience field. Among...
View ArticleDHL pours €2B into healthcare logistics; OXB revenues on the rise
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. DHL Group is spending €2 billion ($2.2 billion) over the next five...
View ArticleInsight Partners' Scott Barclay on mental health investing
For years, investors have poured billions into mental health startups, making it the top-funded area in digital health. But it’s possible we still haven’t seen the company that’s going to ...
View ArticleRFK Jr. talks vaccines, job cuts in his first network interview as HHS chief
In the roughly two months since Robert F. Kennedy Jr. took over as head of HHS, his public appearances have been largely curated and controlled, with limited questions from reporters about his tenure...
View ArticleNovartis follows Lilly and J&J in announcing multibillion-dollar US...
With US tariffs on pharmaceuticals likely to come "very soon," another of the world's largest drugmakers is announcing plans to beef up their American manufacturing. On Thursday, Swiss-based Novartis...
View ArticleFDA is reversing return-to-office mandate for some workers
Less than a month after the Trump administration ordered all FDA employees to come back to their offices full-time, agency leaders have told some staff that remote work will return, multiple FDA ...
View ArticleIra Mellman joins PICI; ViiV Healthcare CMO replaces Chris Corsico at GSK
After 17 years at Genentech, Ira Mellman is joining the Parker Institute for Cancer Immunotherapy as president of research. The PICI, founded by tech entrepreneur Sean Parker, is a key funder ...
View ArticleTome Bio founders wrangle ‘jumping genes’ for new gene insertion tool
Two Boston scientists say they have developed a new gene editing tool based on mysterious "jumping genes" known as retrotransposons, which can copy and paste themselves to hop around the genome. While...
View ArticleCDMOs anticipate inspection bottlenecks after FDA firings
CDMOs fear that FDA site inspections might slow down due to the mass staffing cuts at the federal health agencies. While President Donald Trump's potential pharma tariffs have all drugmakers on alert ...
View ArticleArgenx’s Vyvgart Hytrulo syringe is approved in the US; Opthea to cut 65% of...
Plus, news about Protagonist Therapeutics, Pfizer and Keros Therapeutics: Argenx wins FDA approval for Vyvgart Hytrulo syringe: The subcutaneous injection, which comes in a more convenient prefilled...
View ArticleRecruiters say some biopharmas pause hiring as they struggle to make sense of...
An already bleak biotech market has become more daunting for job seekers, particularly executives. It’s a gut punch for those who have been holding out hope for brighter days since 2022, when the...
View ArticleBristol Myers' immunotherapy combo nets two new approvals
Bristol Myers Squibb’s combined immunotherapies Opdivo and Yervoy won approval this week as a first-line treatment for metastatic liver cancer and certain forms of colorectal cancer. Both approvals...
View ArticleFDA unveils plan to replace animal testing with organoids
Newly-installed FDA Commissioner Marty Makary announced a plan to begin phasing out animal testing in drug development, particularly for monoclonal antibodies. How long that takes remains to be seen....
View ArticleBiotech’s survival guide; What tariffs could mean for pharma; Congress pushes...
Welcome back to Endpoints Weekly! This week's recap kicks off with Andrew Dunn's examination of the biotech playbook for surviving market turmoil. As former Alnylam CEO John Maraganore put it, recent...
View Article